組織診断の世界市場の予測 ～2022年：免疫組織化学・In situハイブリダイゼーション・デジタルパソロジー&ワークフロー
Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology & Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End User - Global Forecast to 2022
|組織診断の世界市場の予測 ～2022年：免疫組織化学・In situハイブリダイゼーション・デジタルパソロジー&ワークフロー|
ページ情報: 英文 162 Pages
世界の組織診断の市場は予測期間中6.9%のCAGR (年間複合成長率) で推移し、2017年の36億8000万米ドルから、2022年には51億4000万米ドルの規模に成長すると予測されています。癌の有病率の上昇や医療費の拡大、癌診断インフラの改善、組織診断技術の進歩などの要因が同市場の主な成長推進因子となっています。
The tissue diagnostics market is expected to reach USD 5.14 billion by 2022 from USD 3.68 billion in 2017, at a CAGR of 6.9%. Factors driving the growth of this market include the rising incidence of cancer, growing healthcare expenditure, improving infrastructure for cancer diagnosis, and technological advancements in tissue diagnostics. On the other hand, complex regulatory frameworks that delay the approval of new diagnostic products and lack of infrastructure are expected to challenge market growth to a certain extent.
The tissue diagnostics market by disease, is categorized into breast cancer, gastric cancer, lymphoma, prostate cancer, NSCLC, and other diseases. The breast cancer segment is expected to grow at the highest CAGR during the forecast period. The growing use of tissue diagnostics for the diagnosis of breast cancer, increasing awareness regarding breast cancer, and the development of novel products are the key factor driving the growth of this market.
By end user, the tissue diagnostics market is segmented into hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users. The research laboratories segment is expected to remain the fastest-growing segment of the global tissue diagnostics market during the forecast period. Factors such as the rising number of cancer drug trials and growing research activities to design novel biomarkers for tissue diagnosis are driving the growth of this segment.
Geographically, the tissue diagnostics market is dominated by North America, followed by Europe in 2017, however, Asia is estimated to grow at the fastest rate during the forecast period. Growth in this region can be attributed to developing healthcare infrastructure, rising burden of cancer, and increasing initiatives to promote the use of novel technologies for tissue diagnostics in Asian countries.
The primary interviews conducted for this report can be categorized as follows:
The key players in the tissue diagnostics market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Merck (Germany), Sakura Finetek Japan (Japan), Abcam (UK), BD (US), QIAGEN (Netherlands), Sienna Cancer Diagnostics (Australia), Royal Philips (Netherlands), A. Menarini Diagnostics (Italy), Cell Signaling Technology (US), Enzo Life Sciences (US), Master Diagnostica (Spain), TissueGnostics (Austria), Bio SB (US), MedImmune (US), Cernostics (US), Zenalux Biomedical (US), 3DHISTECH (Hungary), Lunaphore Technologies (Switzerland), BioGenex (US), and Biocare Medical (US).
The report analyses the tissue diagnostics market by product, technology, disease, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
*Details on Business Overview, Strength of product Portfolio, Business Strategy Excellence, Recent Developments, might not be captured in case of unlisted companies.